



**PATENTS**

Attorney Docket No. 37522-1001C2

**EXPRESS MAIL LABEL INFORMATION - 37 CFR 1.10**

Express Mail Label No.: EL912436322US; mailed February 26, 2002

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re New Utility Patent Application:

Of:

J.P. Bourguignon, Liege, Belgium

For: New peptide antagonists at glutamate and NMDA receptors

**Box DAC**

Commissioner for Patents  
Washington, D.C. 20231

Sir:

**PRELIMINARY AMENDMENT**

Please amend the above-identified new application, submitted concurrently herewith, as follows:

**In the Abstract:**

Please add an Abstract, on the following page.

1006704-005609

## ABSTRACT

Peptide antagonists of glutamate receptors and a subtype of glutamate receptors [NMDA (N-methyl-D-aspartate) receptors] influence glutamate receptor- and NMDA receptor-controlled cells, such as neurons or glial cells in the central nervous system; and can be used in the treatment of acute or chronic disorders of the central nervous system and the treatment of hypoxic, ischemic, and metabolic brain disorders.

**In the Specification:**

At page 1, before line 5, insert a new subtitle and paragraph, and a second new subtitle, to read as follows:

Cross-reference to related applications

This application is a continuation of pending Application No. 08/991,566, filed December 16, 1997; which is a continuation of Application No. 08/549,798, filed November 9, 1995, now US Patent No. 5,804,550. Application No. 08/549,798 is a 371 of PCT International Application No. PCT/SE94/00454, filed May 16, 1994. PCT International Application No. PCT/SE94/00454 claims the priority under 35 USC 119 of Swedish Application No. 9301667-3, filed May 14, 1993.

Field of the Invention

**In the Claims:**

Cancel claim 1.

Add new claims 27-29, to read as follows:

27. A method for the treatment of a brain condition associated with receptor-mediated excitatory effects, selected from the group consisting of hypoxic, ischemic, and metabolic brain disorders, brain injuries, and chronic degenerative brain states, comprising administering a peptide that acts as an antagonist of glutamate receptors in the central nervous system in an amount effective to prevent the excitatory effects.

28. The method of claim 27 where the peptide is (1-3)IGF-I.


29. The method of claim 27 where the condition is stroke.

30. The method of claim 28 where the condition is stroke.

**REMARKS**

Entry of this amendment is respectfully requested. No new matter is added by the amendment, as new claims 27-30 are fully supported by the application as originally filed.

Respectfully submitted,



Derek P. Freyberg  
Attorney for Applicants  
Registration No. 29,250

Customer No. 25213  
Heller Ehrman White & McAuliffe LLP  
275 Middlefield Road  
Menlo Park CA 94025-3506  
(650) 324-7014  
February 26, 2002